Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167)
:1167
Want to see HK:1167 full AI Analyst Report?
Top Page
Jacobio Pharmaceuticals Group Co., Ltd.
(1167)
Select Model
Select Model
Rating:37Underperform
Price Target:
HK$5.00
▼(-37.97% Downside)
Action:DowngradedDate:02/04/26
The score is primarily constrained by weak financial performance (persistent losses and negative operating/free cash flow) despite a cash-heavy balance sheet. Technicals add downside risk given a clear downtrend across moving averages and negative MACD, with oversold readings only mildly tempering the outlook. Valuation is also pressured by negative earnings (negative P/E) and no dividend support.
Positive Factors
Strong liquidity
A cash-rich balance sheet with negative net debt provides durable runway for clinical programs and reduces immediate refinancing pressure. This liquidity supports ongoing trials, partner negotiations and milestone-driven development over the next several months without forced asset sales or urgent dilutive raises.
Negative Factors
Persistent net losses
Ongoing net losses indicate the company is not yet self-sustaining and will likely need external funding to progress clinical programs. Over months this trend can dilute shareholder value, constrain strategic choices, and pressure management to prioritize short-term financing over long-term value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity
A cash-rich balance sheet with negative net debt provides durable runway for clinical programs and reduces immediate refinancing pressure. This liquidity supports ongoing trials, partner negotiations and milestone-driven development over the next several months without forced asset sales or urgent dilutive raises.
Read all positive factors
Jacobio Pharmaceuticals Group Co., Ltd. (1167) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.60B
Dividend YieldN/A
Average Volume (3M)7.94M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-65.87%
EPS Growth6.71%
CountryHK
Employees257
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding791,755,070
10 Day Avg. Volume5,388,349
30 Day Avg. Volume7,936,853
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.00
Price to Sales (P/S)5.94
P/FCF Ratio-10.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.00Price Target Upside36.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.4
Revenue Forecast (FY)HK$723.51M
Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model
Company Description
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology r...
How the Company Makes Money
Jacobio Pharmaceuticals generates revenue through several key streams, including the sale of its proprietary drug products once they receive regulatory approval and are commercialized. The company also engages in collaborative partnerships with ot...
Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
50
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.39M | 155.71M | 63.52M | 95.75M | 152.81M | 486.29M |
| Gross Profit | 41.66M | 155.71M | 3.20M | 12.63M | 12.83M | 442.17M |
| EBITDA | -148.46M | -192.36M | -325.73M | -355.80M | -289.83M | -1.50B |
| Net Income | -144.53M | -155.71M | -359.12M | -371.86M | -301.19M | -1.51B |
Balance Sheet | ||||||
| Total Assets | 1.30B | 1.36B | 1.46B | 1.57B | 1.72B | 1.87B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.17B | 1.15B | 1.28B | 1.54B | 1.63B |
| Total Debt | 165.24M | 152.08M | 209.91M | 147.79M | 6.81M | 10.65M |
| Total Liabilities | 533.92M | 435.99M | 387.11M | 292.12M | 84.75M | 81.15M |
| Stockholders Equity | 770.96M | 923.18M | 1.07B | 1.28B | 1.64B | 1.79B |
Cash Flow | ||||||
| Free Cash Flow | -56.36M | -86.21M | -402.86M | -308.92M | -158.63M | 67.87M |
| Operating Cash Flow | -55.44M | -74.12M | -364.20M | -292.42M | -147.49M | 78.83M |
| Investing Cash Flow | -89.64M | 256.22M | -48.00M | -686.32M | 161.67M | -215.56M |
| Financing Cash Flow | 11.20M | 21.28M | 246.28M | -9.85M | 109.06M | 1.28B |
Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis
Positive
8.06
Price Trends
6.55
Positive
7.00
Positive
7.42
Positive
Market Momentum
0.37
Negative
66.45
Neutral
85.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Positive. The current price of 8.06 is above the 20-day moving average (MA) of 7.11, above the 50-day MA of 6.55, and above the 200-day MA of 7.42, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 66.45 is Neutral, neither overbought nor oversold. The STOCH value of 85.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1167.
Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.49B | -16.66 | -14.53% | ― | -32.12% | -393.23% | |
53 Neutral | HK$3.60B | 15.94 | 5.53% | ― | -12.90% | 33.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.09B | -14.44 | -27.70% | ― | -100.00% | 50.29% | |
44 Neutral | HK$2.44B | -3.21 | -137.11% | ― | ― | 2.11% | |
42 Neutral | HK$15.57B | -15.44 | -64.19% | ― | -33.37% | -339.10% | |
37 Underperform | HK$5.60B | -31.16 | -17.64% | ― | -65.87% | 6.71% |
* Healthcare Sector Average
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
7.14
3.25
83.55%
HK:1873
Viva Biotech Holdings
1.71
0.20
13.25%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.58
2.59
130.15%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
5.07
-2.72
-34.92%
HK:2616
CStone Pharmaceuticals
9.42
6.56
229.37%
HK:3681
SinoMab Bioscience Ltd.
1.50
-0.06
-3.85%
Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events
Jacobio Strikes Up to US$1.9 Billion Global KRAS Inhibitor Deal With AstraZeneca
Dec 21, 2025
Jacobio Pharmaceuticals has entered into a global licence and collaboration agreement with AstraZeneca for its pan-KRAS inhibitor JAB-23E73, granting AstraZeneca exclusive rights to develop, register, manufacture and commercialize the drug worldwi...
Jacobio Pharmaceuticals Secures RMB125 Million to Advance Oncology Pipeline
Dec 2, 2025
Jacobio Pharmaceuticals Group Co., Ltd. announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital as part of a Capital Increase Agreement and Equity Transfer Agreement. This financial boos...
Jacobio’s KRAS G12C and SHP2 Therapy Shows Promising Results in Clinical Trials
Dec 1, 2025
Jacobio Pharmaceuticals Group Co., Ltd. has announced that the Phase I/IIa clinical study results of its KRAS G12C inhibitor glecirasib, combined with the SHP2 inhibitor JAB-3312, have been published in The Lancet Respiratory Medicine. This study,...
Jacobio Pharmaceuticals Appoints Dr. Andrea Wang-Gillam as Co-CEO to Boost Global Strategy
Nov 12, 2025
Jacobio Pharmaceuticals Group Co., Ltd. has announced the appointment of Dr. Andrea Wang-Gillam as Co-Chief Executive Officer, effective November 12, 2025. This strategic move aims to enhance the company’s global strategic deployment and ope...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.